belzutifan
Belzutifan, sold under the brand name Welireg, is an anti-cancer medication used for the treatment of von Hippel–Lindau disease-associated renal cell carcinoma. It is taken by mouth. Belzutifan is an hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor.
Key facts
- Drug.MedlinePlus
- a621047
- Drug.DailyMedID
- Belzutifan
- Drug.pregnancy_AU
- D
- Drug.image
- Belzutifan.svg
- Drug.image_class
- skin-invert-image
- Drug.tradename
- Welireg
- Drug.routes_of_administration
- By mouth
- Drug.class
- Antineoplastic
- Drug.ATC_prefix
- L01
- Drug.ATC_suffix
- XX74
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_UK
Article
8 sectionsContents
- Medical uses
- Adverse effects
- History
- Society and culture
- Legal status
- See also
- References
- External links
{{Infobox drug | image = Belzutifan.svg | image_class = skin-invert-image | width = | alt = | caption =
| pronounce = | tradename = Welireg | Drugs.com = | MedlinePlus = a621047 | DailyMedID = Belzutifan | pregnancy_AU = D | pregnancy_AU_comment = | pregnancy_category= | routes_of_administration = By mouth | class = Antineoplastic | ATC_prefix = L01 | ATC_suffix = XX74 | ATC_supplemental =